Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 15/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.69 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | MLYCD | O95822 | 1/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13873287 | 0.88 | EPHX2 (0.77) | EPHX2CYP2C9CYP2C19POLBEPHX1 | |
| SCHEMBL13634099 | 0.88 | EPHX2 (0.75) | EPHX2CYP2C9CYP2C19POLBBLM | |
| SCHEMBL14413880 | 0.81 | EPHX2 (1.00) | EPHX2CYP2C9CYP2C19POLBEPHX1 | |
| SCHEMBL13873290 | 0.81 | EPHX2 (1.00) | EPHX2CYP2C9CYP2C19POLBEPHX1 | |
| SCHEMBL23486691 | 0.81 | TSHR (0.60) | EPHX2CYP2C9CYP2C19BLM | |
| SCHEMBL13873289 | 0.80 | EPHX2 (0.75) | EPHX2CYP2C9CYP2C19POLBEPHX1 | |
| SCHEMBL4558228 | 0.79 | EPHX2 (0.91) | EPHX2CYP2C9CYP2C19POLB | |
| SCHEMBL13873298 | 0.79 | EPHX2 (1.00) | EPHX2CYP2C9CYP2C19POLBEPHX1 | |
| SCHEMBL14965755 | 0.78 | EPHX2 (0.50) | EPHX2CYP2C9CYP2C19POLB | |
| SCHEMBL23573338 | 0.78 | EPHX2 (0.72) | EPHX2CYP2C9CYP2C19POLBEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090111791-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111791-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-30 | — | — | US | disclosed |
| WO-2007106705-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS AND METHODS OF USING SAME | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111791-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | EPHX1, EPHX2, NCEH1 | EPHX2 2/4885CYP2C9 477/4885CYP2C19 1179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.